AD-120A

AD-120A is an investigational small molecule drug developed by Addpharma for the treatment of gastroesophageal reflux disease (GERD). It is being evaluated in clinical trials alongside a related compound, AD-120, to compare their pharmacokinetic and pharmacodynamic characteristics as well as safety profiles in healthy adult volunteers. Both drugs are administered orally in tablet form before breakfast over a 7-day period. The primary focus of current studies is on the reduction of gastric acidity and assessment of plasma concentration-time curves, with endpoints including area under the curve (AUC) and time to peak concentration (Tmax). The precise mechanism of action or molecular target for AD-120A has not been disclosed publicly; however, its development context suggests it may act similarly to other GERD therapies that reduce gastric acid secretion[1][3][4][8].